Five Prime News Today

"NK Cell Therapy Clinical Trials"(Las Vegas, Nevada, United States)  As per DelveInsight’s assessment, globally, NK Cell Therapy pipeline constitutes 100+ key companies continuously working towards developing

Wang, who joins Harpoon from Hummingbird Bioscience, has a background of 15 years in biopharma business development and finance.

January 2023 Developing next-generation immunotherapies that address cancer immune resistance KA Disclaimers and other information Cautionary... | January 5, 2023

Amgen’s drug portfolio boasts several biologic drugs that are blockbuster sellers. In acquiring ChemoCentryx for $3.7 billion, the pharmaceutical giant gains a company entirely focused on developing small molecule alternatives to biologic medicines.

MRVI earnings call for the period ending June 30, 2022.

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2022. Key results include: Total revenues increased 1% to $6.6...

Eli Lilly Accused of Defrauding Government in $60 Million Qui Tam Suit - In a qui tam suit alleging that Eli Lilly and Co. (“Eli Lilly”) violated the False Claims Act, a...

Amgen Inc. (NASDAQ:NASDAQ:AMGN) Q1 2022 Results Conference Call April 27, 2022 05:00 PM ET Company Participants Arvind Sood - VP, IR Bob Bradway - Chairman and CEO Peter Griffith - CFO...

Amgen Inc. shared its fourth quarter and full-year financial results, with a subsequent announcement that it plans to spend $6 billion buying back shares during the first quarter.

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2021 versus comparable periods in 2020. Key results...